On July 12, 2026, clinical oncologists internationally highlighted the transition of multiple myeloma therapies to subcutaneous formulations, offering faster administration and improved patient comfort. Navigating access to these specialized biologics like Darzalex Faspro (Daratumumab) 1800mg Injection has become a focal point of modern oncology patient navigation.

At Onco Medicine, we specialize in the global sourcing and GDP-certified cold-chain delivery of advanced cancer immunotherapies. By facilitating secure direct importing, we support clinics and patients in USA, Europe, and Australia with original, temperature-tracked biological products.

Subcutaneous Injection vs. Intravenous Infusion

• Reduced Administration Time: While standard IV Darzalex requires hours of hospital infusion, Darzalex Faspro is administered via a subcutaneous injection in just 3 to 5 minutes, significantly lowering clinical burden.
• Fewer Infusion Reactions: Subcutaneous delivery is associated with a lower rate of systemic infusion-related reactions compared to the IV format, enhancing overall patient safety.
• Optimized Clinical Workflow: Shortened treatment sessions allow hospital clinics to optimize scheduling and reduce patient wait times, making advanced myeloma care highly accessible.

Global Sourcing & Importation Regulatory Pathways

Patients in the USA can source Darzalex Faspro under the FDA Personal Importation policy with a valid clinical prescription. Similarly, Australian clinics access the formulation through the TGA Personal Importation Scheme. In Europe, parallel distribution pathways and direct importation are coordinated to bypass local shortages and optimize specialty drug budgets. Onco Medicine ensures full custom documentation, active telemetry monitoring, and cold-chain compliance (2–8°C) for every dispatch.